Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide ...

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...

Maharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at Lupin's registered office. The pharmaceuti...

As a part of the transaction, Lupin's Australia subsidiary Generic Health will gain access to over 60 registered products having sales of o...

Generic Health, the Australia based wholly-owned subsidiary of Lupin, has entered into a definitive agreement under which Lupin will acquir...

"Sreeji brings to Lupin over 20 years of significant domain expertise and global experience," Lupin said in a statement.

Pithampur Unit-3 facility is involved in the manufacture of metered dose inhalers.

Swaminathan as the CFO of Lupin, was part of some of company's biggest mergers and acquisition in US and Japan

The company reported a consolidated net profit of Rs 547 crore in , down 1.1 per cent, as compared to a net profit of Rs 553 crore in the c...

Lupin is a 'BUY' call with a stop loss of Rs 625.

"Lupin is a buy call with a target price of Rs 655 and stop loss of Rs 619."

The National Stock Exchange (NSE) today announced the inclusion of Lupin and UltraTech Cement in NSE 50-share index Nifty.

Lupin Ltd is a ‘BUY’ call with a target of Rs 596 and a stop loss of Rs 565.

LPI has been granted final approval by the US FDA for its ANDA to market a generic version of Watson's NOR-QD® tablets.

Lupin is picked for day traders and short to medium term traders as well.

In a chat with ET Now, Deepak Mohoni, Director, trendwatchindia.com, talks about Lupin.

Lupin Ltd has settled all ongoing Hatch-Waxman litigation relating to desloratadine tablets, the generic version of Schering-Plough's Clari...